Business Development Deal Architecture
  • Search OnBioBD:

  • OnBioBD OldSkool NEWS:

    - OnBioVC 4Q11 Trend Analysis, now available
    - OnBioVC 1Q12 White Paper, now available
    - OnBioVC 1Q12 Trend Analysis, coming soon

  • FDA Registered Contract Manufacturer

Prosensa Therapeutics (Netherlands) a clinical-stage biopharmaceutical company focused on RNA-modulating therapeutics for Duchenne’s Muscular Dystrophy, Huntington’s disease and myotonic dystrophy, closed a $30.7M Series A financing. Participants include New Enterprise Associates, Abingworth Life Sciences Partners, Gimv, Idinvest Partners and MedSciences Capital.

Acceleron Pharma (Cambridge, MA) is a clinical-stage biopharmaceutical company focused on protein therapeutics for anemia, cancer, Duchenne Muscular Dystrophy and bone loss diseases, closed a $30.4M Series D financing. Participants have included Advanced Technology Ventures, Avalon Ventures, Bessemer Venture Partners, Celgene, Flagship Ventures, MPM Capital, Orbimed, Polaris Ventures, QVT Financial, Sutter Hill Ventures and Venrock.

PTC Therapeutics (South Plainfield, NJ) a clinical-stage small molecule company focused on CF, hemophilia and muscular dystrophy, closed a $50M Series E financing. Participants include The Column Group, Delphi Ventures, CSFB Private Equity, HBM BioVentures and Novo Ventures. Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Prosena (The Netherlands) developer of RNA-based splice modulating therapeutics closed a $25M Series B financing. Participants include GIMV, AGF Management, Abingworth Management, Life Sciences Partnersand MedSciences Capital.

Prosensa (Netherlands) a biotech company focused on RNA interference therapeutics for muscular dystrophies raised $18 million in Series A funding. The deal was led by Abingworth Management and Life Science Partners and were joined by return backer Medsciences Capital.

  

to top of page...